Bill Clarke

Caden Biosciences, Inc. develops assays for G-protein coupled receptors. It serves the pharmaceutical industries. The company was founded in 2000 and is headquartered in Madison, WI.

GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom.

VisualSonics, Inc. developed vivo imaging systems for non-invasive small animal research. The company was founded by F. Stuart Foster in 1999 and headquartered in Toronto, Canada.

Axela, Inc. develops biosensor technology. It offers next generation, commercial stage, multiplex tools that provide enhanced analysis of proteins, DNA and RNA. The firm’s products include Ziplex System, autograph, metabolic, colon and breast cancer, inflammation Xpress chips, diffractive optics technology and sensors, dotLab mX System and dot-Avidin, Ready and Covalent products. The company was founded by M. Cynthia Goh, Richard Loo, B. Jane Goh and Richard McAloney in 2001 and is headquartered in Toronto, Canada.

Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.

Brio Device LLC operates as a medical device company which creates solutions for endotracheal intubation that enables clinicians and first responders to manage airways. It specializes in the R&D and sales and marketing of their airway management devices. The company was founded by Douglas Mullen, Laura McCormick, Sabina Siddiqui and Hannah Hensel in 2011 and is headquartered in Ann Arbor, MI.